MDPI and ACS Style
Vedtofte, L.; Bahne, E.; Foghsgaard, S.; Bagger, J.I.; Andreasen, C.; Strandberg, C.; Gørtz, P.M.; Holst, J.J.; Grønbæk, H.; Svare, J.A.;
et al. One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. J. Clin. Med. 2020, 9, 3213.
https://doi.org/10.3390/jcm9103213
AMA Style
Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, Gørtz PM, Holst JJ, Grønbæk H, Svare JA,
et al. One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine. 2020; 9(10):3213.
https://doi.org/10.3390/jcm9103213
Chicago/Turabian Style
Vedtofte, Louise, Emilie Bahne, Signe Foghsgaard, Jonatan I. Bagger, Camilla Andreasen, Charlotte Strandberg, Peter M. Gørtz, Jens J. Holst, Henning Grønbæk, Jens A. Svare,
and et al. 2020. "One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial" Journal of Clinical Medicine 9, no. 10: 3213.
https://doi.org/10.3390/jcm9103213
